Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788 is registered in ClinicalTrials.gov with Fresenius Kabi as lead sponsor.

NCT NCT06274788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06274788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment
Lead sponsor
Fresenius Kabi
Phase
Observational
Overall status
Recruiting
Start date
December 15, 2024
Completion date
April 1, 2028
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

essential fatty acid deficiency, malnutrition, parenteral nutrition associated liver disease (pnald), pediatric all